"Transfusion" article reviews tool to assess bleeding severity in patients with thrombocytopenia


An article in the November issue of "Transfusion" describes a new tool -- the Bleeding Severity Measurement Scale -- for assessing bleeding severity in patients with chemotherapy-induced thrombocytopenia. The authors state that "[a]lthough various bleeding measures exist, there is no standardized and validated method of assessment of bleeding severity in patients with CIT." The scale includes three grades: Grade 0, no bleeding; Grade 1, not clinically significant bleeding; and Grade 2, clinically significant bleeding. The researchers concluded that use of the scale in clinical trials should provide valid and reliable assessments of bleeding. Continuing medical education credits are being offered for reading and successfully completing a test on the article. Read the abstract or visit the CME website.

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park